IBM recruits partners for life sciences push

By Scarlet Pruitt
Thursday, 21 February, 2002

IBM has rolled out a new set of initiatives directed at business partners in the life sciences.

Big Blue said that it would be recruiting hundreds of new business partners over the next two years, drawing on software developers, resellers, distributors and service providers to make inroads in the life sciences.

The company has already rolled out a number of products aimed at capturing the life sciences market. For example, more than 80 life science applications for drug discovery and development now run on pre-packaged and pre-configured server clusters of IBM eServer systems running the Linux and AIX operating systems, the company said.

The company now hopes to recruit business partners that will use and resell its products, in exchange for getting help from IBM in developing business plans designed to exploit opportunities in the life sciences market.

The company also said that it would link its partners with bioinformatics software vendors and help determine additional skill and educational training requirements needed to enter the marketplace. IBM is offering partners seminars and web-based courses to fulfil these educational needs.

Citing a 2001 study by Frost & Sullivan, IBM said that the IT opportunity in the life sciences market could surpass US$40 billion by 2004 in pharmaceutical, biotechnology, bioinformatics, e-health, government, academia and other market segments.

IBM's Life Science division has already made alliances with a number of companies working in the field, such as software vendors Accelrys and LabBook.

Lion Bioscience, a provider of information and knowledge management solutions to life sciences companies, is working with IBM to improve business management processes within the pharmaceutical R&D community and set new standards for how enterprises analyse and manage scientific and medical data.

Related News

A pre-emptive approach to treating leukaemia relapse

The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...

Long COVID abnormalities appear to resolve over time

Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...

RNA-targeted therapy shows promise for childhood dementia

Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd